Globenewswire·2025-11-07 14:00Core Insights - Nurix Therapeutics, Inc. presented new translational data from its ongoing Phase 1 study of NX-1607, a first-in-class oral inhibitor of CBL-B, at the SITC 2025 Annual Meeting, highlighting its potential in treating advanced solid tumors [1][4] Group 1: Clinical Data and Findings - The new data from the Phase 1a clinical trial showed that NX-1607 resulted in dose-dependent pharmacologic activity, leading to increased peripheral T cell activation and proliferation, particularly in patients with stable disease [2][7] - A case study of a patient with metastatic castration-resistant prostate cancer (mCRPC) indicated that treatment with NX-1607 was associated with an expansion of activated peripheral memory T cell subsets and enhanced immune activation gene signatures [3][7] - The findings suggest that NX-1607 induces peripheral immune activation linked to remodeling of the tumor microenvironment, which may contribute to local tumor control [3][7] Group 2: Mechanism and Rationale - CBL-B inhibition is supported as a novel immune-oncology therapy, with NX-1607 showing signs of immune activation and disease control in heavily pretreated patients [4][6] - The treatment demonstrated dose-dependent pharmacokinetics and pharmacodynamic modulation, confirming target engagement and inhibition of CBL-B-mediated signaling [7] - Transcriptomic analyses revealed dose-dependent enrichment of immune signaling pathways, further supporting the mechanistic link between NX-1607 exposure and immune activation [7] Group 3: Company Overview - Nurix Therapeutics is focused on developing targeted protein degradation medicines for cancer and autoimmune diseases, with a pipeline that includes inhibitors of CBL-B and Bruton's tyrosine kinase [8] - The company is advancing multiple potentially first-in-class or best-in-class therapies, leveraging a fully AI-integrated discovery engine to enhance drug development [8]